Kala Bio Inc (NAS:KALA)
$ 6.0547 -0.0953 (-1.55%) Market Cap: 17.05 Mil Enterprise Value: 5.41 Mil PE Ratio: 0 PB Ratio: 2.55 GF Score: 46/100

Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 02:10PM GMT
Release Date Price: $375 (-2.47%)
Christopher Z. Neyor
JPMorgan Chase & Co, Research Division - Analyst

Morning. I'm Chris Neyor from the U.S. pharma team at JPMorgan. I'm glad to introduce Kala Pharmaceuticals and CEO, Mark Iwicki.

On today's format, we have a presentation followed by a Q&A session with Kala's management team. If you have any questions, you can use the ask your question feature online, and I'll integrate those questions in the Q&A session.

With that, I'll hand it over to Mark.

Mark T. Iwicki
Kala Pharmaceuticals, Inc. - Chairman, President & CEO

Thank you so much, Chris, and good morning, everyone. Thank you for being with us, and we're really pleased to give you an update on Kala Pharmaceuticals.

Just moving to Slide 2, we will be making forward-looking statements today, so please refer to our disclaimers and notices.

I'm moving to Slide 3 now. Kala has been on a mission to become a leader in ophthalmic diseases. We have a portfolio of innovative therapies, 2 marketed products, that utilize our proprietary amplified

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot